Two Ways to Play Biotech: FBT’s Return Edge vs. IBB’s Cost Advantage

Résumé détaillé

Fewer holdings, a higher fee, and a shallower drawdown set these two biotech funds apart in ways that could matter for long-term investors.

The First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) offers a concentrated, equal-weighted approach to biotechnology, while the iShares Biotechnology ETF (NASDAQ:IBB) provides broad-market exposure with significantly more holdings.

Both funds serve as primary vehicles for investors seeking targeted exposure to the high-growth healthcare and biotechnology sectors. While they share a 100% sector focus on healthcare, their underlying benchmarks lead to distinct differences in risk profiles, asset concentrations, and management costs that may influence which fits better in a long-term investment portfolio. Investors often look to these funds to avoid the high risk of holding individual biotech stocks.

Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

The iShares fund is more affordable with an expense ratio of 0.44%, which is 0.11 percentage points lower than the 0.55% charged by the First Trust fund. This cost difference represents the primary ongoing price gap for investors choosing between these two biotech benchmarks. Over long periods, these basis points can accumulate and impact total returns, particularly in a volatile sector like biotechnology where price swings are common. Lower fees can provide a margin of safety when returns are flat or negative.

First Trust NYSE Arca Biotechnology Index Fund focuses on a concentrated portfolio of 30 positions, primarily in the healthcare sector. Its largest positions include Genmab A/S (ADR) (NASDAQ:GMAB) at 4.76%, Regeneron Pharmaceuticals (NASDAQ:REGN) at 4.00%, and ADMA Biologics (NASDAQ:ADMA) at 3.99%. This concentration means individual company performance significantly impacts the fund more than broader diversified funds. It was launched in 2006.

iShares Biotechnology ETF tracks a much…

For…

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.